* pafi \<200 or mechanical ventilation indication * clinically relevant co-infection at admission * pregnancy or lactation * iga deficiency or iga nephropathy * immunoglobulin or plasma administration in the last 60 days * contraindication to transfusion or previous allergy to blood-derived products * do-not-resuscitate status * patients receiving other investigational drug for covid-19 in a clinical trial * any condition, that in opinion of the investigator may increase the risk associated with study participation or interfere with the interpretation of study results.

* pafi \<200 or mechanical ventilation indication * clinically relevant co-infection at admission * pregnancy or lactation * iga deficiency or iga nephropathy * immunoglobulin or plasma administration in the last 60 days * contraindication to transfusion or previous allergy to blood-derived products * do-not-resuscitate status * patients receiving other investigational drug for covid-19 in a clinical trial * any condition, that in opinion of the investigator may increase the risk associated with study participation or interfere with the interpretation of study results.

- pafi <200 or mechanical ventilation indication - clinically relevant co-infection at admission - pregnancy or lactation - iga deficiency or iga nephropathy - immunoglobulin or plasma administration in the last 60 days - contraindication to transfusion or previous allergy to blood-derived products - do-not-resuscitate status - patients receiving other investigational drug for covid-19 in a clinical trial - any condition, that in opinion of the investigator may increase the risk associated with study participation or interfere with the interpretation of study results.

- pafi <200 or mechanical ventilation indication - clinically relevant co-infection at admission - pregnancy or lactation - iga deficiency or iga nephropathy - immunoglobulin or plasma administration in the last 60 days - contraindication to transfusion or previous allergy to blood-derived products - do-not-resuscitate status - patients receiving other investigational drug for covid-19 in a clinical trial - any condition, that in opinion of the investigator may increase the risk associated with study participation or interfere with the interpretation of study results.